tldrdailynews.com logo
Tag

Overall Survival

All articles tagged with #overall survival

Pfizer’s Sigvotatug Vedotin: No Overall Survival advantage in NSCLC Phase 3, but signals in one-prior-therapy patients
health28 days ago

Pfizer’s Sigvotatug Vedotin: No Overall Survival advantage in NSCLC Phase 3, but signals in one-prior-therapy patients

Pfizer reported topline Phase 3 SigVie-002 results in previously treated metastatic non-squamous NSCLC: sigvotatug vedotin did not significantly improve overall survival vs docetaxel in the overall population, but showed a stronger OS and PFS signal in patients with only one prior therapy; exploratory IB6 expression data were inconclusive; safety was manageable; results to be shared at a future medical congress, with ongoing first-line studies in combination with pembrolizumab.

via Business Wire|
#docetaxel#health#non-small-cell-lung-cancer
healthcare1 month ago

LAGOON Trial: Zepzelca Fails to Improve Survival in Second-Line SCLC

Jazz Pharmaceuticals reported top-line Phase 3 LAGOON results in relapsed (second-line) small cell lung cancer showing Zepzelca (lurbinectedin) as monotherapy or with irinotecan did not improve overall survival vs investigators' choice (topotecan or irinotecan). Safety was consistent with known profiles. The findings do not affect Zepzelca's first-line maintenance approval from IMforte and Jazz will discuss next steps with the FDA for the second-line indication; results varied by CNS involvement with no OS benefit in the overall population.

via Jazz Pharmaceuticals|
#healthcare#lagoon-trial#lurbinectedin
Ivonescimab+chemo extends survival in first-line squamous NSCLC at ASCO
health1 month ago

Ivonescimab+chemo extends survival in first-line squamous NSCLC at ASCO

Akeso’s ivonescimab, a PD-1xVEGF bispecific, plus chemotherapy significantly extended overall survival in first-line, untreated squamous NSCLC in the Harmoni-6 trial, cutting death risk by 34% with a median OS of 27.9 months vs 23.7 months (p=0.0017) versus Tevimbra-chemo. The interim China-only ASCO presentation showed benefit across PD-L1–negative and –positive patients, but experts caution the follow-up is immature and point to safety signals and trial eligibility criteria that may limit global applicability, signaling a need for further studies.

via Fierce Pharma|
#harmoni-6#health#ivonescimab
New Pancreatic Cancer Drug Daraxonrasib Delivers Landmark Phase 3 Results
health3 months ago

New Pancreatic Cancer Drug Daraxonrasib Delivers Landmark Phase 3 Results

Revolution Medicines announced that its pancreatic cancer drug daraxonrasib met all primary and secondary endpoints in a Phase 3 trial, nearly doubling median overall survival (13.2 months vs 6.7 months) and reducing the risk of death by about 60% versus chemotherapy, prompting an FDA filing using a Commissioner’s National Priority Voucher; safety was manageable and the company is pursuing second-line use and trials in newly diagnosed patients.

via CNBC|
#daraxonrasib#health#overall-survival
Enhancing Ovarian Cancer Survival Rates through Multidisciplinary Surgical Teams
medical-research2 years ago

Enhancing Ovarian Cancer Survival Rates through Multidisciplinary Surgical Teams

A study published in Annals of Surgical Oncology reveals that implementing a multidisciplinary surgical approach significantly improves overall survival (OS) in patients with ovarian cancer. The study, conducted at Mater University Hospital, found that patients who underwent the new approach experienced a 70% improvement in OS compared to previous therapies. The multidisciplinary surgical team (MDT) approach, which involved collaboration among various surgical disciplines, aimed to eliminate all visible tumors within patients' abdomens. The study also identified residual disease and age as independent predictors of survival. The findings highlight the importance of a multidisciplinary approach in achieving optimal treatment outcomes and improved quality of life for ovarian cancer patients.

via AJMC.com Managed Markets Network|
#medical-research#multidisciplinary-surgical-approach#ovarian-cancer
KEYTRUDA® Shows Promising Results as Adjuvant Therapy for Renal Cell Carcinoma Patients
health2 years ago

KEYTRUDA® Shows Promising Results as Adjuvant Therapy for Renal Cell Carcinoma Patients

Merck's anti-PD-1 therapy, KEYTRUDA, has shown a statistically significant improvement in overall survival (OS) as adjuvant therapy for patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, according to the Phase 3 KEYNOTE-564 trial. This marks the first time a therapy has demonstrated a survival benefit compared to placebo in this patient population. The results build on the previously reported disease-free survival benefit from the same trial. KEYTRUDA's safety profile was consistent with previous studies, and the results will be presented at an upcoming medical meeting and submitted to regulatory authorities.

via Merck|
#adjuvant-therapy#clinical-trial#health